Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Short term Debt (2021 - 2025)

Firefly Neuroscience has reported Short term Debt over the past 5 years, most recently at $478000.0 for Q2 2025.

  • Quarterly results put Short term Debt at $478000.0 for Q2 2025, up 59.33% from a year ago — trailing twelve months through Jun 2025 was $478000.0 (up 59.33% YoY), and the annual figure for FY2024 was $694000.0, changed.
  • Short term Debt for Q2 2025 was $478000.0 at Firefly Neuroscience, down from $694000.0 in the prior quarter.
  • Over the last five years, Short term Debt for AIFF hit a ceiling of $1.0 million in Q1 2023 and a floor of $300000.0 in Q2 2024.
  • Median Short term Debt over the past 5 years was $500000.0 (2021), compared with a mean of $563782.9.
  • Biggest five-year swings in Short term Debt: tumbled 70.0% in 2024 and later surged 59.33% in 2025.
  • Firefly Neuroscience's Short term Debt stood at $402306.0 in 2021, then rose by 5.64% to $425000.0 in 2022, then grew by 17.65% to $500000.0 in 2023, then surged by 38.8% to $694000.0 in 2024, then tumbled by 31.12% to $478000.0 in 2025.
  • The last three reported values for Short term Debt were $478000.0 (Q2 2025), $694000.0 (Q4 2024), and $300000.0 (Q2 2024) per Business Quant data.